Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Sparrow Pharmaceuticals has raised $95.0M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
Sparrow Pharmaceuticals's investors include RA Capital Management, OrbiMed, Forbion Capital Partners, U.S. Venture Partners, RiverVest.
Sparrow Pharmaceuticals is headquartered in Portland, United States.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Sparrow Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sparrow Pharmaceuticals — Funding & Investors." VCBacked, September 24, 2025, https://www.vcbacked.co/company/sparrow-pharmaceuticals. Accessed July 19, 2026.
VCBacked. (2025). Sparrow Pharmaceuticals — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sparrow-pharmaceuticals
{{cite web |title=Sparrow Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/sparrow-pharmaceuticals |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated